Evidence map›Paper›PMID 27336468›Full record

ArticlePloS one2016

Identification of the Single Immunodominant Region of the Native Human CC Chemokine Receptor 6 Recognized by Mouse Monoclonal Antibodies.

Karim Dorgham, Cécile Dejou, Christophe Piesse, Guy Gorochov, Jérôme Pène, Hans Yssel

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Karim DorghamSorbonne Universités, Inserm U1135, UPMC Univ Paris 06 UMRS 1135, Centre d'Immunologie et des Maladies Infectieuses (Cimi-Paris), F-75013, Paris, France.
Cécile DejouInstitut de Recherche en Cancérologie, F-34090, Montpellier, France.
Christophe PiesseSorbonne Universités, UPMC Univ Paris 06, IBPS-FR 3631, Service de Synthèse Peptidique, F-75005, Paris, France.
Guy GorochovSorbonne Universités, Inserm U1135, UPMC Univ Paris 06 UMRS 1135, Centre d'Immunologie et des Maladies Infectieuses (Cimi-Paris), F-75013, Paris, France.
Jérôme PèneInstitute for Regenerative Medicine and Biotherapy, Inserm U1183, F-34295, Montpellier, France.
Hans YsselSorbonne Universités, Inserm U1135, UPMC Univ Paris 06 UMRS 1135, Centre d'Immunologie et des Maladies Infectieuses (Cimi-Paris), F-75013, Paris, France.ORCID http://orcid.org/0000-0001-7454-1836
Inserm · FRSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemokines and their receptors play an important role in cell trafficking and recruitment. The CCR6 chemokine receptor, selectively expressed on leukocyte populations, has been shown to play a deleterious role in the pathogenesis of various chronic inflammatory diseases and, as such, may constitute a prime target in the development of immunotherapeutic treatment. However, to date no neutralizing mouse monoclonal antibodies (mAbs) specific for this chemokine receptor have been reported, whereas information on small molecules capable of interfering with the interaction of CCR6 and its ligands is scant. Here, we report the failure to generate neutralizing mouse mAbs specific for human (hu)CCR6. Immunization of mice with peptides mimicking extracellular domains, potentially involved in CCR6 function, failed to induce Abs reactive with the native receptor. Although the use of NIH-3T3 cells expressing huCCR6 resulted in the isolation of mAbs specific for this receptor, they were not able to block the interaction between huCCR6 and huCCL20. Investigation of the anti-huCCR6 mAbs generated in the present study, as well as those commercially available, show that all mAbs invariably recognize a unique, non-neutralizing, immunodominant region in the first part of its N-terminal domain. Together, these results indicate that the generation of potential neutralizing anti-huCCR6 mAbs in the mouse is unlikely to succeed and that alternative techniques, such as the use of other animal species for immunization, might constitute a better approach to generate such a potentially therapeutic tool for the treatment of inflammatory disease.

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, NeutralizingBinding Sites, AntibodyCell LineChemokine CCL20FemaleHumansImmunizationImmunodominant EpitopesMiceMice, Inbred BALB CNIH 3T3 CellsReceptors, CCR6Recombinant ProteinsAntibodies, MonoclonalAntibodies, NeutralizingCCL20 protein, humanCCR6 protein, humanChemokine CCL20Immunodominant EpitopesReceptors, CCR6Recombinant Proteins

Identifiers

PMID27336468
PMCPMC4919008
OpenAlexW2463460843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.